FDA panel recommends easing restrictions on several peptides, including BPC-157

Key Points:

• An FDA advisory committee narrowly voted to loosen restrictions on four peptides—BPC-157, KPV, TB-500, and MOTS-c—despite strong objections from FDA scientists citing lack of safety data and unclear chemical definitions.
• The peptides, popularized by wellness advocates and public figures, currently exist in a gray market, sold online as "for research use only," and the committee’s vote would allow compounding pharmacies to legally produce them, though they are not FDA-approved drugs.
• FDA scientists expressed significant concerns about insufficient evidence for the peptides’ safety and effectiveness, with some panel members criticizing the scientific basis for the review and the incomplete data available.
• Proponents, including several newly appointed committee members with ties to peptide clinics, argued that approving compounding would improve patient safety by moving use away from unregulated sources and emphasized medical freedom.
• Critics warned that endorsing the peptides without solid scientific backing could mislead the public and potentially cause harm, highlighting ethical concerns about responding to market demand rather than rigorous evidence.